Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Exclusion Criteria

• •1. Patients with other uncontrolled malignancies;
• •2. Previously treated with any CAR-T cell product or other genetically-modified T cell therapy;
• •3. Patients with HIV infection, hepatitis B (HBsAg positive) or hepatitis C（anti-HCV positive);
• •4. Patients with central nervous system involvement by lymphoma ,malignant cells in cerebrospinal fluid or history of brain metastasis;
• •5. Patients with atrial or ventricular involvement by B-cell malignancies;
• •6. Patients with tumor mass require urgent treatment, such as ileus or vascular compression;
• •7. Patients with severe disease or other uncontrolled diseases that were not suitable for this trial, such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, grade 2-3 hypertension;
• •8. Unstable pulmonary embolism, deep venous embolism, or other major arterial/venous thromboembolism events occurred within 30 days prior to randomization. If patients receive anticoagulant therapy, the treatment dose must be stable prior to randomization;
• •9. Any situations that the investigators believes were not suitable for this trial;
• •10. Long-term use of immunosuppressive agents after organ transplantation, except for the patients recently or currently receiving inhaled steroids;
• •11. Pregnant(or lactation) women;
• •12. Patients with severe active infections(excluding simple urinary tract infection and bacterial pharyngitis)within 30 days prior to randomization